Vivekanand Jha's Publications

About Vivekanand Jha's Publications

Executive Director, The George Institute for Global Health, India
  • MD,
  • DM,
  • FRCP,
  • FAMS

  • Cocreation of Integrated Interventions Addressing Noncommunicable Diseases and Environmental Degradation: Protocol for a Participatory Qualitative Study

    JMIR Research Protocols Date published:

  • Convalescent plasma in hospitalised patients with COVID -19

    Internal Medicine Journal Date published:

  • Slowing of progress in reducing non-communicable disease mortality

    Nature Reviews Nephrology Date published:

  • Sibeprenlimab in IgA Nephropathy - Interim Analysis of a Phase 3 Trial

    New England Journal of Medicine Date published:

  • A Phase 3 Trial of Atacicept in Patients with IgA Nephropathy

    New England Journal of Medicine Date published:

  • Risks of Hyperkalemia With Potassium-Enriched Salt Substitute Among Patients Using Concomitant Blockade of the Renin-Angiotensin-Aldosterone System in the Salt Substitute and Stroke Study

    Circulation Date published:

  • Digoxin in rheumatic heart disease: Rationale and design of a multicenter, placebo-controlled double-blind randomized controlled trial (Dig-RHD trial)

    American Heart Journal Date published:

  • Augmenting nephroprotection: balcinrenone plus dapagliflozin in chronic kidney disease

    The Lancet Date published:

  • Global, regional, and national burden of chronic kidney disease in adults, 1990-2023, and its attributable risk factors: a systematic analysis for the Global Burden of Disease Study 2023

    The Lancet Date published:

  • Preliminary effectiveness and feasibility of ASHA-led mobile health intervention for diabetes care in Indian primary health care settings

    Scientific Reports Date published:

  • Prevalence of impaired kidney function & its association with diabetes & hypertension in India: The ICMR-INDIAB study (ICMR-INDIAB-22)

    The Indian Journal of Medical Research Date published:

  • Long-Term Effect of Oral Methylprednisolone on Kidney Outcomes in Patients with IgAN: TESTING-ON, a Post-Trial Observational Study

    Journal of the American Society of Nephrology Date published:

  • #745 Sex differences across treatment response to corticosteroids and kidney outcomes in IgA nephropathy: insights from the TESTING trial

    Nephrology Dialysis Transplantation Date published:

  • Burden of 375 diseases and injuries, risk-attributable burden of 88 risk factors, and healthy life expectancy in 204 countries and territories, including 660 subnational locations, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023

    The Lancet Date published:

  • Global burden of 292 causes of death in 204 countries and territories and 660 subnational locations, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023

    The Lancet Date published:

  • Role of Systemic Glucocorticoids in Reducing IgA and Galactose-Deficient IgA1 Levels in IgA Nephropathy

    Clinical Journal of the American Society of Nephrology Date published: